Turn first binders into development candidates.
We continue where discovery stops: confirming your hits, building structure–activity understanding and optimising potency, stability and developability until you have a lead worth taking forward.
From a sequence to a series.
Hit confirmation
Resynthesis and full characterisation of selected sequences, so every decision rests on authentic, high-purity material.
SAR exploration
Alanine and truncation scans, positional scanning and focused analogue libraries to map which residues drive activity.
Scaffold design
Cyclisation, stapling, non-natural amino acids and N-methylation to lock in the active conformation.
Balance potency with drug-like properties.
Potency & selectivity
Iterative design–make–test cycles, with your assays or our partners’, to improve activity on your target and selectivity against related ones.
Chemical stability
Solution and degradation studies by HPLC and LC-MS, with the findings fed straight back into the next round of design.
Half-life extension
Lipidation, PEGylation and other conjugation strategies to tune exposure and duration of action.
Developability
Solubility, aggregation, impurity profiling and characterisation to flag risks before development.
Biology from specialist partners, chemistry from us.
We focus on peptide chemistry and analytics. When your program needs biology, we arrange it with specialist partner laboratories and coordinate the work for you.
- 01Cell-based assays
Activity and potency testing of your analogues, run by a partner laboratory.
- 02ADME and in vivo studies
Metabolic stability, pharmacokinetic and mouse studies, arranged with specialist pre-clinical partners.
- 03One point of contact
We coordinate the studies, supply the material and connect the results back to your chemistry.
A lead ready for development.
- 01An optimised lead series
Your best candidates and back-ups, with the SAR that explains them.
- 02Decision-ready data
Chemistry, stability and characterisation data, plus any partner biology results, in clear reports for go/no-go decisions.
- 03Material for the next step
Gram-scale material for in vivo studies, and a route our development team can scale towards GMP.
Have a hit? Let’s make it a lead.
Tell us about your sequence, your target profile and the decision you need to make next.